Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pushing Clear all
Completed Not applicable Interventional

Do Adaptable Sockets Improve Military Performance?

NCT04494555
View directory record Official record
Conditions
Amputation Stump
Interventions
Static socket, User adjusted socket, Microprocessor-adjusting sockets
Device
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Not applicable Interventional

Adaptive Interventions for Prevention/Intervention for Youth Substance Abuse

NCT03928756
View directory record Official record
Conditions
Substance Use
Interventions
Push Notifications with Tailored Intervention Content, Push Notifications with Engaging, Non-therapeutic Content, No Push Notifications
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
16 Years to 24 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance

NCT01642030
View directory record Official record
Conditions
Opioid Dependence, Pain, Addiction
Interventions
Placebo, Hydromorphone, Buprenorphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 3 Interventional

A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes

NCT00277043
View directory record Official record
Conditions
Supportive, Ill-defined Sites
Interventions
paclitaxel, docetaxel, taxane, taxane
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

NCT00061893
View directory record Official record
Conditions
Sarcoma
Interventions
celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, conventional surgery, radiation therapy, MESNA, Filgrastim
Drug · Procedure · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 50 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
87
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of ∆-9-THC and Naloxone in Humans

NCT01591629
View directory record Official record
Conditions
Healthy
Interventions
Naloxone, Delta-9-THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional

MRI Sarcoma Non Invasive Thermometry

NCT00093509
View directory record Official record
Conditions
Sarcoma
Interventions
doxorubicin hydrochloride, ifosfamide and mesna, hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Mark Dewhirst
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2014 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

NCT00381862
View directory record Official record
Conditions
Colorectal Cancer, Nausea and Vomiting
Interventions
aprepitant, dexamethasone, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, palonosetron hydrochloride, quality-of-life assessment
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Savannah, Georgia • Hilo, Hawaii • Harvey, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 9, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional Results available

Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma

NCT00031590
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors, Medulloblastoma
Interventions
Cisplatin, Cyclophosphamide, Etoposide, Lomustine, Vincristine, Craniospinal Radiation
Drug · Radiation
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
3 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
3
States / cities
Palo Alto, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Sep 9, 2026, 2:05 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans

NCT06671977
View directory record Official record
Conditions
Major Depression Disorder, Depression
Interventions
DMT-Medium Dose, DMT-Low Dose, THC-Medium Dose, THC-Low Dose
Drug
Lead sponsor
Deepak C. D'Souza
Other
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

NCT04898101
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acalabrutinib, Microtracer [14C]ACP-196
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 9, 2026, 2:05 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

NCT03871257
View directory record Official record
Conditions
Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma
Interventions
Carboplatin, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 21 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
125
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS

NCT02397057
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
Injectafer, Placebo
Drug · Other
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Mobile, Alabama • National City, California • Rancho Mirage, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

NCT00878254
View directory record Official record
Conditions
Mantle-Cell Lymphoma
Interventions
G-CSF, Rituximab, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Ifosfamide, Leucovorin, Mesna, Methotrexate, Vincristine
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Not applicable Interventional

Individual Patient Exposure and Response in Pediatric Lupus

NCT04358302
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Pillsy
Behavioral
Lead sponsor
Duke University
Other
Eligibility
5 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2024 · Synced Sep 9, 2026, 2:05 AM EDT
Terminated Phase 1 Interventional Results available

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

NCT01186328
View directory record Official record
Conditions
Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell, Leukemia, Lymphoblastic, Acute
Interventions
EZN-3042, Cytarabine, Doxorubicin, Prednisone, Vincristine, PEG-asparaginase, Methotrexate, Hydrocortisone
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia

NCT02409459
View directory record Official record
Conditions
Iron Deficiency, Fibromyalgia
Interventions
Injectafer, Placebo
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intern Health Study 2024

NCT06465680
View directory record Official record
Conditions
Depression, Mood, Sleep, Physical Activity
Interventions
Intern Health Study behavioral change mobile notification
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1,047 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

NCT02130869
View directory record Official record
Conditions
Neuroblastoma, Lymphoma, High-risk Tumor
Interventions
CD133+ selected autologous stem cell infusion, IL-2, hu14.18K322A, Busulfan, Melphalan, GM-CSF, Bendamustine, Etoposide, Cytarabine, Carboplatin, Haploidentical natural killer cell infusion, G-CSF, Etoposide phosphate, CliniMACS
Biological · Drug · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intern Health Study: 2020 Cohort Micro-Randomized Trial

NCT05106439
View directory record Official record
Conditions
Telemedicine
Interventions
Intern Health Study competition-related mobile notification, Intern Health Study mobile app, Intern Health Study mobile app competition scoreboard and history
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
2,286 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 9, 2026, 2:05 AM EDT
Withdrawn Phase 2 Interventional

Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy

NCT04223661
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide Pill, Dexamethasone, Daratumumab
Drug
Lead sponsor
Attaya Suvannasankha
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Results available

A Phase Ib/II in Patients With Acute Ischemic Stroke

NCT02963376
View directory record Official record
Conditions
Ischemic Stroke
Interventions
0.05 mL/kg DDFPe, 0.05 mL/kg Placebo, 0.10 mL/kg DDFPe, 0.10 mL/kg Placebo, 0.17 mL/kg DDFPe, 0.17 mL/kg Placebo
Drug
Lead sponsor
NuvOx LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Sep 9, 2026, 2:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women

NCT02272647
View directory record Official record
Conditions
Healthy
Interventions
IM Saline Placebo (0.25 ml), IM Estradiol valerate (2.5 mg), IM Saline Placebo (0.5 ml), IM Estradiol valerate (5.0 mg), Oral Micronized Progesterone, Oral Placebo, Ghrelin (0.3 ug/kg), Medroxyprogesterone - Acetate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 9, 2026, 2:05 AM EDT